Haleon

Haleon plc
Company type	Public limited company
Traded as	LSE: HLN; NYSE: HLN; FTSE 100 component;
ISIN	GB00BMX86B70
Industry	Healthcare; Consumer goods;
Predecessors	GSK Consumer Healthcare; Pfizer Consumer Healthcare(2nd Incarnation); Wyeth Consumer Healthcare; Novartis Consumer Healthcare;
Founded	18 July 2022
Headquarters	Weybridge, England, United Kingdom
Area served	Worldwide
Key people	Sir Dave Lewis (chairman); Brian McNamara (CEO);
Products	Oral hygiene and medicines; nutritional products; over-the-counter medicines;
Brands	Actifed; Advil; Aquafresh; Beechams; Biotene; Caltrate; Centrum; Contac; Emergen-C; Eno; Excedrin; Fenbid; Fenistil; Flonase; Foodles; Loviscol; Maclean; Nexium; Nicorette; Nicotinell; Odol; Otrivin; Panadol; Parodontax; Polident; Sensodyne; Theraflu; Tums; Voltaren;
Revenue	£11,233 million (2024)
Operating income	£2,206 million (2024)
Net income	£1,475 million (2024)
Total assets	£34,315 million (2024)
Total equity	£16,224 million (2024)
Number of employees	24,000 (2024)
Website	www.haleon.com

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 percent market share in 2022.

Haleon was established on 18 July 2022 as a corporate spin-off from GSK.

Sir Dave Lewis is chairman, with Brian McNamara as CEO. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020.